Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Deciphera says first patient treated in Phase 1 DCC-3116 study » 16:01
06/30/21
06/30
16:01
06/30/21
16:01
DCPH

Deciphera

$36.80 /

+0.14 (+0.38%)

Deciphera Pharmaceuticals…

Deciphera Pharmaceuticals announced dose administration for the first patient in the Phase 1, multicenter, open-label, first-in-human study of DCC-3116. DCC-3116 is an investigational ULK kinase inhibitor designed to inhibit autophagy and is being studied as a single agent and in combination with trametinib, a U.S. Food and Drug Administration approved MEK inhibitor, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene. "Approximately one third of all cancers, including a high percentage of pancreatic, lung, colorectal, and melanoma cancers, are driven by mutations in RAS or RAF genes, representing what we believe to be one of the largest unmet medical needs in oncology," said Matthew L. Sherman, MD, Executive Vice President and Chief Medical Officer of Deciphera Pharmaceuticals. "DCC-3116, a first-in-class, highly selective switch-control ULK kinase inhibitor, is designed to suppress autophagy and may offer a novel approach to targeting a broad array of cancers. We look forward to advancing our fourth active clinical development program generated from our switch-control kinase inhibitor platform and further evaluating the role of ULK kinase inhibition and its potential to represent a new treatment paradigm for cancers caused by RAS or RAF mutations."

ShowHide Related Items >><<
DCPH Deciphera
$36.80 /

+0.14 (+0.38%)

DCPH Deciphera
$36.80 /

+0.14 (+0.38%)

05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
03/30/21 Credit Suisse
Deciphera initiated with an Outperform at Credit Suisse
DCPH Deciphera
$36.80 /

+0.14 (+0.38%)

Recommendations
Deciphera price target lowered to $65 from $70 at Barclays » 06:43
05/05/21
05/05
06:43
05/05/21
06:43
DCPH

Deciphera

$43.28 /

-2.45 (-5.36%)

Barclays analyst Peter…

Barclays analyst Peter Lawson lowered the firm's price target on Deciphera Pharmaceuticals to $65 from $70 and keeps an Overweight rating on the shares following the company's Q1 results.

ShowHide Related Items >><<
DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
03/30/21 Credit Suisse
Deciphera initiated with an Outperform at Credit Suisse
02/10/21 JonesTrading
Deciphera should be bought on post-earnings weakness, says JonesTrading
DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

Recommendations
Deciphera price target lowered to $75 from $80 at H.C. Wainwright » 06:13
05/05/21
05/05
06:13
05/05/21
06:13
DCPH

Deciphera

$43.28 /

-2.45 (-5.36%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein lowered the firm's price target on Deciphera Pharmaceuticals to $75 from $80 and keeps a Buy rating on the shares. The analyst believes the Q1 revenue for Qinlock of $20M versus $19.5M in Q4 is directly correlated to fewer diagnoses over physician sentiment despite a 15% quarter-over-quarter growth in prescriber base.

ShowHide Related Items >><<
DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
03/30/21 Credit Suisse
Deciphera initiated with an Outperform at Credit Suisse
02/10/21 JonesTrading
Deciphera should be bought on post-earnings weakness, says JonesTrading
02/10/21 SVB Leerink
Deciphera upgraded to Outperform from Market Perform at SVB Leerink
DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

Recommendations
Deciphera price target lowered to $60 from $75 at Piper Sandler » 04:52
05/05/21
05/05
04:52
05/05/21
04:52
DCPH

Deciphera

$43.28 /

-2.45 (-5.36%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond lowered the firm's price target on Deciphera Pharmaceuticals to $60 from $75 and keeps an Overweight rating on the shares following the company's Q1 results. The shares are likely to come under pressure today, and stay under pressure until the INTRIGUE study readout in Q4, given management's depiction of the state of the Qinlock launch last night, Raymond tells investors in a research note. The analyst says his a 25 doctor survey was "disconnected on so many levels - and simply directionally wrong - versus management commentary."

ShowHide Related Items >><<
DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

03/30/21 Credit Suisse
Deciphera initiated with an Outperform at Credit Suisse
02/10/21 JonesTrading
Deciphera should be bought on post-earnings weakness, says JonesTrading
02/10/21 SVB Leerink
Deciphera upgraded to Outperform from Market Perform at SVB Leerink
02/10/21 Barclays
Deciphera price target lowered to $70 from $85 at Barclays
DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

Earnings
Deciphera reports Q1 EPS ($1.06), consensus ($1.06) » 16:26
05/04/21
05/04
16:26
05/04/21
16:26
DCPH

Deciphera

$43.28 /

-2.45 (-5.36%)

Reports Q1 revenue…

Reports Q1 revenue $25.2M, consensus $22.59M. "We are excited by the continuing successful commercial launch of QINLOCK in the U.S. as we solidify its position among GIST prescribers and patients and expand access to this important medicine globally. We also remain focused on realizing QINLOCK's potential in earlier lines of therapy," said Steve Hoerter, President and Chief Executive Officer of Deciphera. "We expect the INTRIGUE Phase 3 top-line results in the fourth quarter of this year and believe QINLOCK has the potential to transform the treatment of GIST for this larger, second-line patient population. Building on our commitment to fully explore the potential of QINLOCK to benefit patients with GIST, we are excited to announce today our plans to initiate a Phase 1b/2 study combining QINLOCK with binimetinib, an approved MEK inhibitor. Our enthusiasm for this combination is based on compelling pre-clinical data showing that this combination can induce apoptosis and has the potential to deepen and prolong responses."

ShowHide Related Items >><<
DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

03/30/21 Credit Suisse
Deciphera initiated with an Outperform at Credit Suisse
02/10/21 JonesTrading
Deciphera should be bought on post-earnings weakness, says JonesTrading
02/10/21 SVB Leerink
Deciphera upgraded to Outperform from Market Perform at SVB Leerink
02/10/21 Barclays
Deciphera price target lowered to $70 from $85 at Barclays
DCPH Deciphera
$43.28 /

-2.45 (-5.36%)

Over a quarter ago
Conference/Events
Deciphera participates in a conference call with JPMorgan » 13:25
04/07/21
04/07
13:25
04/07/21
13:25
DCPH

Deciphera

$44.98 /

+0.49 (+1.10%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Fye holds a conference call with CEO Hoerter and CFO Kelly on April 7 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
DCPH Deciphera
$44.98 /

+0.49 (+1.10%)

DCPH Deciphera
$44.98 /

+0.49 (+1.10%)

03/30/21 Credit Suisse
Deciphera initiated with an Outperform at Credit Suisse
02/10/21 JonesTrading
Deciphera should be bought on post-earnings weakness, says JonesTrading
02/10/21 SVB Leerink
Deciphera upgraded to Outperform from Market Perform at SVB Leerink
02/10/21 Barclays
Deciphera price target lowered to $70 from $85 at Barclays
DCPH Deciphera
$44.98 /

+0.49 (+1.10%)

Conference/Events
Deciphera participates in a conference call with JPMorgan » 04:55
04/07/21
04/07
04:55
04/07/21
04:55
DCPH

Deciphera

$44.49 /

-1.56 (-3.39%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Fye holds a conference call with CEO Hoerter and CFO Kelly on April 7 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
DCPH Deciphera
$44.49 /

-1.56 (-3.39%)

DCPH Deciphera
$44.49 /

-1.56 (-3.39%)

03/30/21 Credit Suisse
Deciphera initiated with an Outperform at Credit Suisse
02/10/21 JonesTrading
Deciphera should be bought on post-earnings weakness, says JonesTrading
02/10/21 SVB Leerink
Deciphera upgraded to Outperform from Market Perform at SVB Leerink
02/10/21 Barclays
Deciphera price target lowered to $70 from $85 at Barclays
DCPH Deciphera
$44.49 /

-1.56 (-3.39%)

Conference/Events
Deciphera participates in a conference call with JPMorgan » 09:47
04/06/21
04/06
09:47
04/06/21
09:47
DCPH

Deciphera

$46.10 /

+0.05 (+0.11%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Fye holds a conference call with CEO Hoerter and CFO Kelly on April 7 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
DCPH Deciphera
$46.10 /

+0.05 (+0.11%)

DCPH Deciphera
$46.10 /

+0.05 (+0.11%)

03/30/21 Credit Suisse
Deciphera initiated with an Outperform at Credit Suisse
02/10/21 JonesTrading
Deciphera should be bought on post-earnings weakness, says JonesTrading
02/10/21 SVB Leerink
Deciphera upgraded to Outperform from Market Perform at SVB Leerink
02/10/21 Barclays
Deciphera price target lowered to $70 from $85 at Barclays
DCPH Deciphera
$46.10 /

+0.05 (+0.11%)

Hot Stocks
Zai Lab, Deciphera announce China NMPA approval of Qinlock NDA » 05:07
03/31/21
03/31
05:07
03/31/21
05:07
ZLAB

Zai Lab

$129.13 /

+1.41 (+1.10%)

, DCPH

Deciphera

$41.50 /

+1.03 (+2.55%)

Zai Lab (ZLAB) and…

Zai Lab (ZLAB) and Deciphera (DCPH) announced that the China National Medical Products Administration, or NMPA, has approved its new drug application, or NDA, for Qinlock for the treatment of adult patients with advanced gastrointestinal stromal tumors, or GIST, who have received prior treatment with three or more kinase inhibitors, including imatinib. Qinlock targets the broad spectrum of KIT and PDGFRa mutations known to drive GIST. Deciphera and Zai Lab are also exploring the use of Qinlock to treat patients with second-line GIST. Deciphera has completed target enrollment in the Phase 3 INTRIGUE study of Qinlock in patients with second-line GIST, with top-line results anticipated in the second half of 2021.

ShowHide Related Items >><<
ZLAB Zai Lab
$129.13 /

+1.41 (+1.10%)

DCPH Deciphera
$41.50 /

+1.03 (+2.55%)

ZLAB Zai Lab
$129.13 /

+1.41 (+1.10%)

02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
01/15/21 Citi
Citi boosts Zai Lab target to $216, adds to U.S. Focus List
01/07/21 Wedbush
Argenx price target raised to $293 from $283 at Wedbush
11/16/20 JPMorgan
Zai Lab price target raised to $111 from $101 at JPMorgan
DCPH Deciphera
$41.50 /

+1.03 (+2.55%)

03/30/21 Credit Suisse
Deciphera initiated with an Outperform at Credit Suisse
02/10/21 JonesTrading
Deciphera should be bought on post-earnings weakness, says JonesTrading
02/10/21 SVB Leerink
Deciphera upgraded to Outperform from Market Perform at SVB Leerink
02/10/21 Barclays
Deciphera price target lowered to $70 from $85 at Barclays
ZLAB Zai Lab
$129.13 /

+1.41 (+1.10%)

DCPH Deciphera
$41.50 /

+1.03 (+2.55%)

Initiation
Deciphera initiated with an Outperform at Credit Suisse » 16:19
03/30/21
03/30
16:19
03/30/21
16:19
DCPH

Deciphera

$41.50 /

+1.03 (+2.55%)

Credit Suisse analyst…

Credit Suisse analyst Brad Canino initiated coverage of Deciphera Pharmaceuticals with an Outperform rating and $78 price target. The analyst is positive on the stock based on his analysis of the probability of success of the Qinlock second-line gastrointestinal stromal tumor pivotal trial, which he believes is high. If successful, Deciphera will exit 2021 with a $600M U.S. sales opportunity for Qinlock and two pipeline assets potentially started in pivotal trials, "which increases the likelihood of the shares moving appreciably higher," Canino tells investors in a research note.

ShowHide Related Items >><<
DCPH Deciphera
$41.50 /

+1.03 (+2.55%)

DCPH Deciphera
$41.50 /

+1.03 (+2.55%)

02/10/21 JonesTrading
Deciphera should be bought on post-earnings weakness, says JonesTrading
02/10/21 SVB Leerink
Deciphera upgraded to Outperform from Market Perform at SVB Leerink
02/10/21 Barclays
Deciphera price target lowered to $70 from $85 at Barclays
02/04/21 Piper Sandler
Deciphera selloff at odds with 'bullish' oncologist survey, says Piper Sandler
DCPH Deciphera
$41.50 /

+1.03 (+2.55%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.